Stock Markets April 23, 2026 06:23 AM

Norway’s Sovereign Wealth Fund Weighs Potential Stake in SpaceX

Deputy CEO confirms discussions as fund reports a large first-quarter loss amid market pressures

By Leila Farooq
Norway’s Sovereign Wealth Fund Weighs Potential Stake in SpaceX

Norway’s $2.2 trillion sovereign wealth fund is evaluating whether to take an investment position in SpaceX, the fund’s deputy CEO said. The potential deal comes as SpaceX readies what is expected to be a $1.75 trillion initial public offering this summer. The fund disclosed a first-quarter loss of 636 billion crowns ($68.44 billion), attributed in part to regional conflict weighing on global equities.

Key Points

  • Norway’s sovereign wealth fund manages approximately $2.2 trillion and is assessing a potential investment in SpaceX.
  • SpaceX is preparing a $1.75 trillion initial public offering, expected this summer and potentially among the largest IPOs ever.
  • The fund reported a first-quarter loss of 636 billion crowns ($68.44 billion), citing effects from the war in the Middle East on global stocks.

OSLO, April 23 - Norway’s $2.2 trillion sovereign wealth fund is assessing a possible investment in SpaceX, the fund’s deputy CEO confirmed on Thursday. The rocket and satellite company controlled by Elon Musk is slated to pursue a $1.75 trillion initial public offering, an offering that is expected to take place this summer and could rank among the largest on record.

When asked about whether the fund had been approached to participate as an investor, Deputy CEO Trond Grande said in an interview: "we have dialogue with companies, right? So, we also have dialogue with SpaceX." Asked directly if the fund was evaluating whether such an opportunity could be of interest, Grande replied: "That is what we are doing." He declined to provide further details.

The comments came the same day the fund released first-quarter financial results showing a loss of 636 billion crowns, equivalent to $68.44 billion. The fund attributed part of the strain on its portfolio to the impact of the war in the Middle East on global stock markets.

The discussion over SpaceX follows the company’s move toward an extraordinarily large share sale. The potential $1.75 trillion IPO, planned for this summer, would represent a significant event in capital markets if it proceeds as outlined. Norway’s sovereign wealth fund, which manages roughly $2.2 trillion in assets, regularly engages in dialogue with corporations as part of its investment processes, and Grande’s comments confirm such engagement is occurring in this instance.

Grande did not expand on the nature of the talks or indicate any timeline for a decision. The fund’s openness to dialogue with SpaceX is consistent with its general investment approach, but whether the assessment will result in a commitment remains unspecified.


Contextual note: The fund’s reported first-quarter loss and its consideration of a potential SpaceX investment were disclosed on the same day, but no linkage beyond timing and concurrent reporting was provided by the deputy CEO.

Risks

  • Uncertainty over whether the assessment of a SpaceX investment will lead to an actual participation - this affects capital markets and the aerospace/technology sector.
  • Market volatility tied to geopolitical conflict (the war in the Middle East) has contributed to the fund’s significant quarterly loss, impacting global equities and sovereign fund returns.
  • Lack of disclosed details or timeline on talks leaves outcome and potential scale of any investment unclear - this introduces uncertainty for investors tracking both the fund and SpaceX.

More from Stock Markets

RELX Shares Slip After Anthropic Forms Legal AI Partnership with Freshfields Apr 23, 2026 Super Micro Shares Slide After Reported $1.1B-$1.4B Oracle Rack Cancellation Apr 23, 2026 Unprofitable Tech Giants Poised to Drive Largest IPO Wave on Record Apr 23, 2026 FTSE 100 Slips as Oil Rallies and Prospects for U.S.-Iran Talks Dim Apr 23, 2026 Roche CEO Warns Bureaucracy and Pricing Moves Threaten Europe’s Position in Drug Innovation Apr 23, 2026